leadf
logo-loader
viewValiRx PLC

ValiRx says its treatment had a “clear impact on patients with prostate cancer”

The drug developer was at pains to stress this was only a very preliminary inference from the data measuring prostate-specific antigens and supported by tumour imagin

ValiRx PLC -

ValiRx PLC (LON:VAL) said the initial feedback from a phase I/II study of VAL201 showed the treatment had a “clear impact on patients with prostate cancer”.

The drug developer was at pains to stress this was only a very preliminary inference from the data measuring prostate-specific antigens and supported by tumour imaging.

ValiRx went on to confirm VAL201 was safe, with a “high degree of tolerability”.

According to a study by Bristol University, prostate cancer is the most common form of the disease in men in the UK. Worldwide, meanwhile, there were an estimated 1.3mln new cases last year.

"I look forward to regulatory approval of the trial data being speedily reached and the opportunity of potentially demonstrating that VAL201 can address this widespread and often fatal disease in men," said ValiRx chief executive, Dr Satu Vanikka.

The results, along with a full statistical and scientific analysis, will be submitted to the drug regulator after which they will be made publicly available, the company said. No timeline was given.

In the meantime, the preliminary observations are expected to be presented at cancer conferences.

Quick facts: ValiRx PLC

Price: 40 GBX

AIM:VAL
Market: AIM
Market Cap: £23.44 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read